163 related articles for article (PubMed ID: 27726213)
1. Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
Dagan E; Gershoni-Baruch R; Kurolap A; Fried G
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27726213
[TBL] [Abstract][Full Text] [Related]
2. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
4. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
5. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
6. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
7. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
8. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.
Laitman Y; Borsthein RT; Stoppa-Lyonnet D; Dagan E; Castera L; Goislard M; Gershoni-Baruch R; Goldberg H; Kaufman B; Ben-Baruch N; Zidan J; Maray T; Soussan-Gutman L; Friedman E
Breast Cancer Res Treat; 2011 Jun; 127(2):489-95. PubMed ID: 20960228
[TBL] [Abstract][Full Text] [Related]
10. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer.
Dagan E
Genet Test; 2008 Jun; 12(2):267-71. PubMed ID: 18439109
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma.
Bruchim I; Amichay K; Kidron D; Attias Z; Biron-Shental T; Drucker L; Friedman E; Werner H; Fishman A
Int J Gynecol Cancer; 2010 Oct; 20(7):1148-53. PubMed ID: 21206239
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
13. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
14. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
15. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
[TBL] [Abstract][Full Text] [Related]
16. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.
Gershoni-Baruch R; Dagan E; Fried G; Bruchim Bar-Sade R; Sverdlov-Shiri R; Zelicksson G; Friedman E
Eur J Cancer; 2000 May; 36(8):983-6. PubMed ID: 10885601
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer.
Gershoni-Baruch R; Dagan E; Fried G; Kepten I; Robinson E
Eur J Hum Genet; 1999; 7(7):833-6. PubMed ID: 10573018
[TBL] [Abstract][Full Text] [Related]
18. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Lee JS; Wacholder S; Struewing JP; McAdams M; Pee D; Brody LC; Tucker MA; Hartge P
J Natl Cancer Inst; 1999 Feb; 91(3):259-63. PubMed ID: 10037104
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
Shih HA; Couch FJ; Nathanson KL; Blackwood MA; Rebbeck TR; Armstrong KA; Calzone K; Stopfer J; Seal S; Stratton MR; Weber BL
J Clin Oncol; 2002 Feb; 20(4):994-9. PubMed ID: 11844822
[TBL] [Abstract][Full Text] [Related]
20. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Robson ME; Chappuis PO; Satagopan J; Wong N; Boyd J; Goffin JR; Hudis C; Roberge D; Norton L; Bégin LR; Offit K; Foulkes WD
Breast Cancer Res; 2004; 6(1):R8-R17. PubMed ID: 14680495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]